158 related articles for article (PubMed ID: 11426841)
1. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide.
Calignano A; La Rana G; Piomelli D
Eur J Pharmacol; 2001 May; 419(2-3):191-8. PubMed ID: 11426841
[TBL] [Abstract][Full Text] [Related]
2. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
3. Control of pain initiation by endogenous cannabinoids.
Calignano A; La Rana G; Giuffrida A; Piomelli D
Nature; 1998 Jul; 394(6690):277-81. PubMed ID: 9685157
[TBL] [Abstract][Full Text] [Related]
4. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
5. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.
Beaulieu1 P; Bisogno1 T; Punwar S; Farquhar-Smith WP; Ambrosino G; Di Marzo V; Rice AS
Eur J Pharmacol; 2000 May; 396(2-3):85-92. PubMed ID: 10822060
[TBL] [Abstract][Full Text] [Related]
6. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes.
Rockwell CE; Kaminski NE
J Pharmacol Exp Ther; 2004 Nov; 311(2):683-90. PubMed ID: 15284281
[TBL] [Abstract][Full Text] [Related]
7. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.
Oz M; Yang KH; Dinc M; Shippenberg TS
J Pharmacol Exp Ther; 2007 Nov; 323(2):547-54. PubMed ID: 17682128
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
[TBL] [Abstract][Full Text] [Related]
10. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways.
Yoshihara S; Morimoto H; Ohori M; Yamada Y; Abe T; Arisaka O
Int Arch Allergy Immunol; 2005 Sep; 138(1):80-7. PubMed ID: 16103691
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
12. Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats.
Trezza V; Vanderschuren LJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):343-50. PubMed ID: 18948500
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.
Helyes Z; Németh J; Thán M; Bölcskei K; Pintér E; Szolcsányi J
Life Sci; 2003 Sep; 73(18):2345-53. PubMed ID: 12941436
[TBL] [Abstract][Full Text] [Related]
15. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin.
Hohmann AG; Farthing JN; Zvonok AM; Makriyannis A
J Pharmacol Exp Ther; 2004 Feb; 308(2):446-53. PubMed ID: 14610224
[TBL] [Abstract][Full Text] [Related]
16. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
17. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
[TBL] [Abstract][Full Text] [Related]
18. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
19. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Romero TR; Pacheco Dda F; Duarte ID
Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
[TBL] [Abstract][Full Text] [Related]
20. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
Jaggar SI; Hasnie FS; Sellaturay S; Rice AS
Pain; 1998 May; 76(1-2):189-99. PubMed ID: 9696473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
